



# SAFETY DATA SHEET

**100-0281 100-0282 - Anti-Mouse IFN-gamma Antibody, Clone XMG1.2, FITC**

Revision Date 28-Feb-2023

Revision Number 1.1

## 1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND OF THE COMPANY/UNDERTAKING

### Product identifier

**Product Name** Anti-Mouse IFN-gamma Antibody, Clone XMG1.2, FITC

DocuSigned by:

*Ruth Gill*

1A130E8E320B4F...  
2023-03-03

### Other means of identification

**Catalog Number** 100-0281 100-0282

**Document Number** 10000007837

**Synonyms** None

### Recommended use of the chemical and restrictions on use

**Recommended Use** Laboratory reagent

### Details of the supplier of the safety data sheet

#### Manufacturer/Supplier

STEMCELL Technologies Canada Inc.  
Suite 500 - 1618 Station Street  
Vancouver, British Columbia V6A 1B6 Canada

#### Emergency telephone number

**Emergency Telephone** 1-800-667-0322

## 2. HAZARDS IDENTIFICATION

### Classification

This chemical is not considered hazardous by the 2012 OSHA Hazard Communication Standard (29 CFR 1910.1200)

### Hazards not otherwise classified (HNOC)

Not applicable

### Label elements

#### Hazard statements

Not a hazardous substance or mixture according to the Globally Harmonized System (GHS)



# SAFETY DATA SHEET

**100-0281 100-0282 - Anti-Mouse IFN-gamma Antibody, Clone XMG1.2, FITC**

Revision Date 28-Feb-2023  
Revision Number 1.1

The product contains no substances which at their given concentration, are considered to be hazardous to health.

**Appearance** Clear

**Physical state** Liquid

**Odor** No data available

## Other Information

Not applicable

**Unknown acute toxicity** 0 % of the mixture consists of ingredient(s) of unknown toxicity  
 0 % of the mixture consists of ingredient(s) of unknown acute oral toxicity  
 100 % of the mixture consists of ingredient(s) of unknown acute dermal toxicity  
 100 % of the mixture consists of ingredient(s) of unknown acute inhalation toxicity (gas)  
 100 % of the mixture consists of ingredient(s) of unknown acute inhalation toxicity (vapor)  
 0 % of the mixture consists of ingredient(s) of unknown acute inhalation toxicity (dust/mist)

## 3. COMPOSITION/INFORMATION ON INGREDIENTS

### Substance

Not applicable.

### Mixture

Not a hazardous substance or mixture according to the Globally Harmonized System (GHS)

\*The exact percentage (concentration) of composition has been withheld as a trade secret.

## 4. FIRST AID MEASURES

### Description of first aid measures

<b>Inhalation</b>	Remove to fresh air.
<b>Eye contact</b>	Rinse thoroughly with plenty of water for at least 15 minutes, lifting lower and upper eyelids. Consult a physician.
<b>Skin contact</b>	Wash skin with soap and water.



# SAFETY DATA SHEET

**100-0281 100-0282 - Anti-Mouse IFN-gamma Antibody, Clone XMG1.2, FITC**

Revision Date 28-Feb-2023

Revision Number 1.1

**Ingestion** Clean mouth with water and drink afterwards plenty of water.

## Most important symptoms and effects, both acute and delayed

**Symptoms** No information available.

## Indication of any immediate medical attention and special treatment needed

**Note to physicians** Treat symptomatically.

## 5. FIRE-FIGHTING MEASURES

**Suitable Extinguishing Media** Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.

**Unsuitable extinguishing media** CAUTION: Use of water spray when fighting fire may be inefficient.

**Specific hazards arising from the chemical** No information available.

### Explosion data

**Sensitivity to Mechanical Impact** None.

**Sensitivity to Static Discharge** None.

**Special protective equipment for fire-fighters** Firefighters should wear self-contained breathing apparatus and full firefighting turnout gear. Use personal protection equipment.

## 6. ACCIDENTAL RELEASE MEASURES

### Personal precautions, protective equipment and emergency procedures

**Personal precautions** Ensure adequate ventilation.

### Environmental precautions

**Environmental precautions** See Section 12 for additional Ecological Information.

### Methods and material for containment and cleaning up

**Methods for containment** Prevent further leakage or spillage if safe to do so.



# SAFETY DATA SHEET

**100-0281 100-0282 - Anti-Mouse IFN-gamma Antibody, Clone XMG1.2, FITC**

Revision Date 28-Feb-2023  
Revision Number 1.1

**Methods for cleaning up** Pick up and transfer to properly labeled containers.

**Prevention of secondary hazards** Clean contaminated objects and areas thoroughly observing environmental regulations.

## 7. HANDLING AND STORAGE

### Precautions for safe handling

**Advice on safe handling** Handle in accordance with good industrial hygiene and safety practice.

### Conditions for safe storage, including any incompatibilities

**Storage Conditions** Store in accordance with information listed on the Product Information Sheet (PIS).

## 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

### Control parameters

**Exposure Limits** This product, as supplied, does not contain any hazardous materials with occupational exposure limits established by the region specific regulatory bodies.

### Appropriate engineering controls

**Engineering controls** Showers  
Eyewash stations  
Ventilation systems.

### Individual protection measures, such as personal protective equipment

**Eye/face protection** No special protective equipment required.

**Skin and body protection** No special protective equipment required.

**Respiratory protection** No protective equipment is needed under normal use conditions. If exposure limits are exceeded or irritation is experienced, ventilation and evacuation may be required.

**General hygiene considerations** Handle in accordance with good industrial hygiene and safety practice.



# SAFETY DATA SHEET

**100-0281 100-0282 - Anti-Mouse IFN-gamma Antibody, Clone XMG1.2, FITC**

Revision Date 28-Feb-2023

Revision Number 1.1

## 9. PHYSICAL AND CHEMICAL PROPERTIES

### Information on basic physical and chemical properties

Physical state	Liquid
Appearance	Clear
Color	No information available
Odor	No data available
Odor threshold	No data available

<u>Property</u>	<u>Values</u>	<u>Remarks • Method</u>
pH	No data available	None known
Melting point / freezing point	No data available	None known
Boiling point / boiling range	No data available	None known
Flash point	No data available	None known
Evaporation rate	No data available	None known
Flammability (solid, gas)	No data available	None known
Flammability Limit in Air		None known
Upper flammability limit:	No data available	
Lower flammability limit:	No data available	
Vapor pressure	No data available	None known
Vapor density	No data available	None known
Relative density	No data available	None known
Water solubility	No data available	None known
Solubility in other solvents	No data available	None known
Partition coefficient	No data available	None known
Autoignition temperature	No data available	None known
Decomposition temperature	No data available	None known
Kinematic viscosity	No data available	None known
Dynamic viscosity	No data available	None known
Explosive properties	No data available	None known
Oxidizing properties	No information available	

### Other Information

Softening point	No information available
Molecular weight	No information available
Molecular formula	No information available
VOC Content (%)	No information available
Liquid Density	No information available
Bulk density	No information available

## 10. STABILITY AND REACTIVITY

Reactivity	No information available.
Chemical stability	Stable under recommended transport or storage conditions.



# SAFETY DATA SHEET

**100-0281 100-0282 - Anti-Mouse IFN-gamma Antibody, Clone XMG1.2, FITC**

Revision Date 28-Feb-2023

Revision Number 1.1

**Possibility of hazardous reactions** None under normal processing.

**Conditions to avoid** None known based on information supplied.

**Incompatible materials** None known based on information supplied.

**Hazardous decomposition products** None known based on information supplied.

## 11. TOXICOLOGICAL INFORMATION

### Information on likely routes of exposure

#### Product Information

**Inhalation** Specific test data for the substance or mixture is not available.

**Eye contact** Specific test data for the substance or mixture is not available.

**Skin contact** Specific test data for the substance or mixture is not available.

**Ingestion** Specific test data for the substance or mixture is not available.

### Symptoms related to the physical, chemical and toxicological characteristics

**Symptoms** No information available.

### Numerical measures of toxicity

#### Acute toxicity

**Unknown acute toxicity** 0 % of the mixture consists of ingredient(s) of unknown toxicity  
 0 % of the mixture consists of ingredient(s) of unknown acute oral toxicity  
 100 % of the mixture consists of ingredient(s) of unknown acute dermal toxicity  
 100 % of the mixture consists of ingredient(s) of unknown acute inhalation toxicity (gas)  
 100 % of the mixture consists of ingredient(s) of unknown acute inhalation toxicity (vapor)  
 0 % of the mixture consists of ingredient(s) of unknown acute inhalation toxicity (dust/mist)

Product Information

### Delayed and immediate effects as well as chronic effects from short and long-term exposure

**Skin corrosion/irritation** No information available.

Product Information



# SAFETY DATA SHEET

**100-0281 100-0282 - Anti-Mouse IFN-gamma Antibody, Clone XMG1.2, FITC**

Revision Date 28-Feb-2023  
Revision Number 1.1

**Serious eye damage/eye irritation** No information available.

Product Information

**Respiratory or skin sensitization** No information available.

Product Information

**Germ cell mutagenicity** No information available.

Product Information

**Carcinogenicity** No information available.

**Reproductive toxicity** No information available.

Product Information

**STOT - single exposure** No information available.

Product Information

**STOT - repeated exposure** No information available.

Product Information

**Aspiration hazard** No information available.

## 12. ECOLOGICAL INFORMATION

**Ecotoxicity**

Product Information

**Persistence and degradability** No information available.

**Bioaccumulation** There is no data for this product.

**Other adverse effects** No information available.

## 13. DISPOSAL CONSIDERATIONS

**Waste treatment methods**

**Waste from residues/unused products** Dispose of in accordance with local regulations. Dispose of waste in accordance with environmental legislation.

**Contaminated packaging** Do not reuse empty containers.



# SAFETY DATA SHEET

**100-0281 100-0282 - Anti-Mouse IFN-gamma Antibody, Clone XMG1.2, FITC**

Revision Date 28-Feb-2023

Revision Number 1.1

US EPA Waste Number P105

## 14. TRANSPORT INFORMATION

<u>DOT</u>	Not regulated
<u>TDG</u>	Not regulated
<u>MEX</u>	Not regulated
<u>ICAO (air)</u>	Not regulated
<u>IATA</u>	Not regulated
<u>IMDG</u>	Not regulated
<u>RID</u>	Not regulated
<u>ADR</u>	Not regulated
<u>ADN</u>	Not regulated

## 15. REGULATORY INFORMATION

### International Inventories

TSCA	Complies
DSL/NDSL	Complies
EINECS/ELINCS	Complies
ENCS	Does not comply
IECSC	Complies
KECL	Complies
PICCS	Complies
AICS	Complies

### Legend:

**TSCA** - United States Toxic Substances Control Act Section 8(b) Inventory

**DSL/NDSL** - Canadian Domestic Substances List/Non-Domestic Substances List

**EINECS/ELINCS** - European Inventory of Existing Chemical Substances/European List of Notified Chemical Substances

**ENCS** - Japan Existing and New Chemical Substances

**IECSC** - China Inventory of Existing Chemical Substances

**KECL** - Korean Existing and Evaluated Chemical Substances





# SAFETY DATA SHEET

**100-0281 100-0282 - Anti-Mouse IFN-gamma Antibody, Clone XMG1.2, FITC**

Revision Date 28-Feb-2023

Revision Number 1.1

**PICCS** - Philippines Inventory of Chemicals and Chemical Substances

**AICS** - Australian Inventory of Chemical Substances

## US Federal Regulations

### SARA 313

Section 313 of Title III of the Superfund Amendments and Reauthorization Act of 1986 (SARA). This product does not contain any chemicals which are subject to the reporting requirements of the Act and Title 40 of the Code of Federal Regulations, Part 372.

### SARA 311/312 Hazard Categories

Acute health hazard	No
Chronic Health Hazard	No
Fire hazard	No
Sudden release of pressure hazard	No
Reactive Hazard	No

### CWA (Clean Water Act)

This product does not contain any substances regulated as pollutants pursuant to the Clean Water Act (40 CFR 122.21 and 40 CFR 122.42).

### CERCLA

This material, as supplied, does not contain any substances regulated as hazardous substances under the Comprehensive Environmental Response Compensation and Liability Act (CERCLA) (40 CFR 302) or the Superfund Amendments and Reauthorization Act (SARA) (40 CFR 355). There may be specific reporting requirements at the local, regional, or state level pertaining to releases of this material.

## US State Regulations

### California Proposition 65

This product does not contain any Proposition 65 chemicals.

## U.S. State Right-to-Know Regulations

### US State Regulations

Chemical name	New Jersey	Massachusetts	Pennsylvania
Water 7732-18-5	-	-	X
Sodium Azide 26628-22-8	X	X	X

## U.S. EPA Label Information



# SAFETY DATA SHEET

**100-0281 100-0282 - Anti-Mouse IFN-gamma Antibody, Clone XMG1.2, FITC**

Revision Date 28-Feb-2023  
Revision Number 1.1

EPA Pesticide Registration Number Not applicable

## 16. OTHER INFORMATION, INCLUDING DATE OF PREPARATION OF THE LAST REVISION

Prepared By, Quality Control. STEMCELL Technologies Canada Inc.

Revision Date 28-Feb-2023

Revision Note No information available.

### Disclaimer

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information given is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and is not to be considered a warranty or quality specification. The information relates only to the specific material designated and may not be valid for such material used in combination with any other materials or in any process, unless specified in the text. STEMCELL Technologies Inc. shall not be held liable for any damage resulting from handling or from contact with the product.

**End of Safety Data Sheet**

**Certificate Of Completion**

Envelope Id: C28C204BB63D4B6AAB59469B4219DD0F	Status: Completed
Subject: Complete with DocuSign: 10000007837-SDS_1_1.pdf	
Source Envelope:	
Document Pages: 10	Signatures: 1
Certificate Pages: 5	Initials: 0
AutoNav: Enabled	Envelope Originator:
Enveloped Stamping: Enabled	Cory Thomson
Time Zone: (UTC-08:00) Pacific Time (US & Canada)	1618 Station Street
	Suite 500
	Vancouver, BC V6A 1B6
	cory.thomson@stemcell.com
	IP Address: 207.216.179.12

**Record Tracking**

Status: Original 2023-03-03   06:15	Holder: Cory Thomson cory.thomson@stemcell.com	Location: DocuSign
--	---	--------------------

**Signer Events**

Ruth Gill  
ruth.gill@stemcell.com  
Program Lead, Official Documentation  
Security Level: Email, Account Authentication (None)

**Signature**

DocuSigned by:  
*Ruth Gill*  
1A130E8E320B4AF...  
Signature Adoption: Pre-selected Style  
Using IP Address: 50.68.4.162

**Timestamp**

Sent: 2023-03-03 | 06:16  
Viewed: 2023-03-03 | 08:08  
Signed: 2023-03-03 | 08:09

**Electronic Record and Signature Disclosure:**  
Accepted: 2021-03-09 | 09:57  
ID: 31751331-06db-4fcc-aecd-87e677f32d84

**In Person Signer Events**

**Signature**

**Timestamp**

**Editor Delivery Events**

**Status**

**Timestamp**

**Agent Delivery Events**

**Status**

**Timestamp**

**Intermediary Delivery Events**

**Status**

**Timestamp**

**Certified Delivery Events**

**Status**

**Timestamp**

**Carbon Copy Events**

**Status**

**Timestamp**

Sharon McAuliffe  
sharon.mcauliffe@stemcell.com  
Security Level: Email, Account Authentication (None)

**COPIED**

Sent: 2023-03-03 | 08:09

**Electronic Record and Signature Disclosure:**  
Accepted: 2023-02-06 | 09:51  
ID: d3613b64-739c-4528-9db6-5aac2c0b1cba

Paula Liao  
paula.liao@stemcell.com  
Security Level: Email, Account Authentication (None)

**COPIED**

Sent: 2023-03-03 | 08:09  
Viewed: 2023-03-03 | 12:25

**Electronic Record and Signature Disclosure:**  
Not Offered via DocuSign

QAS Document Control  
qasdocumentcontrol@stemcell.com  
Security Level: Email, Account Authentication (None)

**COPIED**

Sent: 2023-03-03 | 08:09  
Viewed: 2023-03-03 | 12:56

<b>Carbon Copy Events</b>	<b>Status</b>	<b>Timestamp</b>
---------------------------	---------------	------------------

**Electronic Record and Signature Disclosure:**  
Accepted: 2022-05-17 | 11:26  
ID: 2ee418fd-3f48-4d7e-bf1e-7156f1149617

<b>Witness Events</b>	<b>Signature</b>	<b>Timestamp</b>
-----------------------	------------------	------------------

<b>Notary Events</b>	<b>Signature</b>	<b>Timestamp</b>
----------------------	------------------	------------------

<b>Envelope Summary Events</b>	<b>Status</b>	<b>Timestamps</b>
--------------------------------	---------------	-------------------

Envelope Sent	Hashed/Encrypted	2023-03-03   06:16
Certified Delivered	Security Checked	2023-03-03   08:08
Signing Complete	Security Checked	2023-03-03   08:09
Completed	Security Checked	2023-03-03   08:09

<b>Payment Events</b>	<b>Status</b>	<b>Timestamps</b>
-----------------------	---------------	-------------------

<b>Electronic Record and Signature Disclosure</b>
---

## **CONSUMER DISCLOSURE**

From time to time, Stemcell Technologies Inc (we, us or Company) may be required by law to provide to you certain written notices or disclosures. Described below are the terms and conditions for providing to you such notices and disclosures electronically through the DocuSign, Inc. (DocuSign) electronic signing system. Please read the information below carefully and thoroughly, and if you can access this information electronically to your satisfaction and agree to these terms and conditions, please confirm your agreement by clicking the 'I agree' button at the bottom of this document.

### **Getting paper copies**

At any time, you may request from us a paper copy of any record provided or made available electronically to you by us. You will have the ability to download and print documents we send to you through the DocuSign system during and immediately after signing session and, if you elect to create a DocuSign signer account, you may access them for a limited period of time (usually 30 days) after such documents are first sent to you. After such time, if you wish for us to send you paper copies of any such documents from our office to you, you will be charged a \$0.00 per-page fee. You may request delivery of such paper copies from us by following the procedure described below.

### **Withdrawing your consent**

If you decide to receive notices and disclosures from us electronically, you may at any time change your mind and tell us that thereafter you want to receive required notices and disclosures only in paper format. How you must inform us of your decision to receive future notices and disclosure in paper format and withdraw your consent to receive notices and disclosures electronically is described below.

### **Consequences of changing your mind**

If you elect to receive required notices and disclosures only in paper format, it will slow the speed at which we can complete certain steps in transactions with you and delivering services to you because we will need first to send the required notices or disclosures to you in paper format, and then wait until we receive back from you your acknowledgment of your receipt of such paper notices or disclosures. To indicate to us that you are changing your mind, you must withdraw your consent using the DocuSign 'Withdraw Consent' form on the signing page of a DocuSign envelope instead of signing it. This will indicate to us that you have withdrawn your consent to receive required notices and disclosures electronically from us and you will no longer be able to use the DocuSign system to receive required notices and consents electronically from us or to sign electronically documents from us.

### **All notices and disclosures will be sent to you electronically**

Unless you tell us otherwise in accordance with the procedures described herein, we will provide electronically to you through the DocuSign system all required notices, disclosures, authorizations, acknowledgements, and other documents that are required to be provided or made available to you during the course of our relationship with you. To reduce the chance of you inadvertently not receiving any notice or disclosure, we prefer to provide all of the required notices and disclosures to you by the same method and to the same address that you have given us. Thus, you can receive all the disclosures and notices electronically or in paper format through the paper mail delivery system. If you do not agree with this process, please let us know as described below. Please also see the paragraph immediately above that describes the consequences of your electing not to receive delivery of the notices and disclosures electronically from us.

**How to contact Stemcell Technologies Inc:**

You may contact us to let us know of your changes as to how we may contact you electronically, to request paper copies of certain information from us, and to withdraw your prior consent to receive notices and disclosures electronically as follows:

To contact us by email send messages to: adam.leggett@stemcell.com

**To advise Stemcell Technologies Inc of your new e-mail address**

To let us know of a change in your e-mail address where we should send notices and disclosures electronically to you, you must send an email message to us at adam.leggett@stemcell.com and in the body of such request you must state: your previous e-mail address, your new e-mail address. We do not require any other information from you to change your email address..

In addition, you must notify DocuSign, Inc. to arrange for your new email address to be reflected in your DocuSign account by following the process for changing e-mail in the DocuSign system.

**To request paper copies from Stemcell Technologies Inc**

To request delivery from us of paper copies of the notices and disclosures previously provided by us to you electronically, you must send us an e-mail to adam.leggett@stemcell.com and in the body of such request you must state your e-mail address, full name, US Postal address, and telephone number. We will bill you for any fees at that time, if any.

**To withdraw your consent with Stemcell Technologies Inc**

To inform us that you no longer want to receive future notices and disclosures in electronic format you may:

- i. decline to sign a document from within your DocuSign session, and on the subsequent page, select the check-box indicating you wish to withdraw your consent, or you may;
- ii. send us an e-mail to adam.leggett@stemcell.com and in the body of such request you must state your e-mail, full name, US Postal Address, and telephone number. We do not need any other information from you to withdraw consent.. The consequences of your withdrawing consent for online documents will be that transactions may take a longer time to process..

**Required hardware and software**

Operating Systems:	Windows® 2000, Windows® XP, Windows Vista®; Mac OS® X
Browsers:	Final release versions of Internet Explorer® 6.0 or above (Windows only); Mozilla Firefox 2.0 or above (Windows and Mac); Safari™ 3.0 or above (Mac only)
PDF Reader:	Acrobat® or similar software may be required to view and print PDF files
Screen Resolution:	800 x 600 minimum

Enabled Security Settings:	Allow per session cookies
----------------------------	---------------------------

\*\* These minimum requirements are subject to change. If these requirements change, you will be asked to re-accept the disclosure. Pre-release (e.g. beta) versions of operating systems and browsers are not supported.

**Acknowledging your access and consent to receive materials electronically**

To confirm to us that you can access this information electronically, which will be similar to other electronic notices and disclosures that we will provide to you, please verify that you were able to read this electronic disclosure and that you also were able to print on paper or electronically save this page for your future reference and access or that you were able to e-mail this disclosure and consent to an address where you will be able to print on paper or save it for your future reference and access. Further, if you consent to receiving notices and disclosures exclusively in electronic format on the terms and conditions described above, please let us know by clicking the 'I agree' button below.

By checking the 'I agree' box, I confirm that:

- I can access and read this Electronic CONSENT TO ELECTRONIC RECEIPT OF ELECTRONIC CONSUMER DISCLOSURES document; and
- I can print on paper the disclosure or save or send the disclosure to a place where I can print it, for future reference and access; and
- Until or unless I notify Stemcell Technologies Inc as described above, I consent to receive from exclusively through electronic means all notices, disclosures, authorizations, acknowledgements, and other documents that are required to be provided or made available to me by Stemcell Technologies Inc during the course of my relationship with you.